A Complete Pathological Response to Pembrolizumab following ex vivo Liver Resection in a Patient with Colorectal Liver Metastases | Zendy

Maria BaimasGeorge | Zendy; E. Baker | Zendy; Michal Kamionek | Zendy; John Stuart Salmon | Zendy; Amit Sastry | Zendy; David Levi | Zendy; Dionisios Vrochides | Zendy

Open Access

A Complete Pathological Response to Pembrolizumab following ex vivo Liver Resection in a Patient with Colorectal Liver Metastases

Author(s) -

Maria BaimasGeorge,

E. Baker,

Michal Kamionek,

John Stuart Salmon,

Amit Sastry,

David Levi,

Dionisios Vrochides

Publication year - 2018

Publication title -

chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.539

H-Index - 54

eISSN - 1421-9794

pISSN - 0009-3157

DOI - 10.1159/000487814

Subject(s) - medicine , pembrolizumab , colorectal cancer , chemotherapy , hepatectomy , ex vivo , oncology , immunotherapy , pathological , resection , gastroenterology , cancer , in vivo , surgery , biology , microbiology and biotechnology

Advances in the systemic treatment of stage IV colorectal cancer with liver metastases has offered improved survival rates for patients who otherwise face a dismal prognosis. However, a pathologically complete response (PCR) to chemotherapy for colorectal liver metastases is still rare, and its significance is not fully understood. In this case report, we describe a patient who achieved PCR after neoadjuvant immunotherapy with pembrolizumab and a left hepatectomy using an ex vivo resection technique.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research